SEC Form 4 · accession 0001209191-15-047703

PHARMACYCLICS INC · PCYC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Robert F. Booth

Director

Period of report

May 26, 2015

Accepted (ET)

May 28, 2015 · 7:01 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000949699

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	May 26, 2015	D	10,000	$261.25	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy)^F2	$5.76	May 26, 2015	D	10,000	D	—	Dec 9, 2020	Common Stock	10,000	D
Stock Option (Right to Buy)^F2	$5.81	May 26, 2015	D	20,000	D	—	Dec 31, 2020	Common Stock	20,000	D
Stock Option (Right to Buy)^F2	$6.01	May 26, 2015	D	3,743	D	—	Apr 1, 2021	Common Stock	3,743	D
Stock Option (Right to Buy)^F2	$10.58	May 26, 2015	D	2,126	D	—	Jul 1, 2021	Common Stock	2,126	D
Stock Option (Right to Buy)^F2	$11.31	May 26, 2015	D	1,989	D	—	Oct 3, 2021	Common Stock	1,989	D
Stock Option (Right to Buy)^F2	$14.26	May 26, 2015	D	7,500	D	—	Dec 15, 2021	Common Stock	7,500	D
Stock Option (Right to Buy)^F2	$15.02	May 26, 2015	D	1,754	D	—	Jan 3, 2022	Common Stock	1,754	D
Stock Option (Right to Buy)^F2	$28.47	May 26, 2015	D	800	D	—	Apr 2, 2022	Common Stock	800	D
Stock Option (Right to Buy)^F2	$59.28	May 26, 2015	D	440	D	—	Jul 2, 2022	Common Stock	440	D
Stock Option (Right to Buy)^F2	$65.56	May 26, 2015	D	442	D	—	Oct 1, 2022	Common Stock	442	D
Stock Option (Right to Buy)^F2	$49.00	May 26, 2015	D	7,500	D	—	Nov 9, 2022	Common Stock	7,500	D
Stock Option (Right to Buy)^F2	$61.44	May 26, 2015	D	425	D	—	Jan 2, 2023	Common Stock	425	D
Stock Option (Right to Buy)^F2	$79.67	May 26, 2015	D	307	D	—	Apr 1, 2023	Common Stock	307	D
Stock Option (Right to Buy)^F2	$74.48	May 26, 2015	D	3,750	D	—	May 9, 2023	Common Stock	3,750	D
Stock Option (Right to Buy)^F2	$85.39	May 26, 2015	D	322	D	—	Jul 1, 2023	Common Stock	322	D
Stock Option (Right to Buy)^F2	$139.89	May 26, 2015	D	205	D	—	Oct 1, 2023	Common Stock	205	D
Stock Option (Right to Buy)^F2	$108.44	May 26, 2015	D	224	D	—	Jan 2, 2024	Common Stock	224	D
Stock Option (Right to Buy)^F2	$107.42	May 26, 2015	D	240	D	—	Apr 1, 2024	Common Stock	240	D
Stock Option (Right to Buy)^F2	$95.08	May 26, 2015	D	3,750	D	—	May 9, 2024	Common Stock	3,750	D
Stock Option (Right to Buy)^F2	$89.58	May 26, 2015	D	424	D	—	Jul 1, 2024	Common Stock	424	D
Stock Option (Right to Buy)^F2	$115.80	May 26, 2015	D	314	D	—	Oct 1, 2024	Common Stock	314	D
Stock Option (Right to Buy)^F2	$124.46	May 26, 2015	D	294	D	—	Jan 2, 2025	Common Stock	294	D
Stock Option (Right to Buy)^F2	$257.015	May 26, 2015	D	158	D	—	Apr 7, 2025	Common Stock	158	D

Explanation of responses

F1Represents shares issuable pursuant to a Restricted Stock Unit Award that was cancelled in exchange for a cash payment, subject to applicable withholding taxes and pursuant to the procedures terms set forth in the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie.
F2This option was cancelled pursuant to the terms of the Merger Agreement in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.